与myc结合亲和力高的已上市药物

MYC有所谓不可成药性，还没有专门的靶向药上市。

目前针对myc实际可行的治疗策略是根据患者除myc突变扩增外的其他突变，抑制其他靶点，如mtor、hsp90等，实现合成致死或蛋白降解。自救群里部分myc扩增的乳腺癌患者用了mtor抑制剂，确有疗效。
- H# c0 l( k9 _: M, s$ M
针对治疗myc还有一种办法是通过计算机虚拟筛选等办法，在已上市药物里找与myc结合亲和力高的药物。
7 T* N- q: ?8 o1 m% Q5 U
《In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia》这篇论文，通过Virtual Screening、Molecular Docking Analyses and Microscale Thermophoresis的办法，从FDA已经批准上市的1578种药物里，筛选出一些与MYC结合亲和力高的药物；其中一些药物与MYC的结合亲和力超过常用的c-MYC 抑制剂试剂 10058-F4 和 10074-G5(LBEs of −4.92 kcal/mol and −6.24 kcal/mol)。
" c2 \# r) @2 G) Q8 \
  D0 H8 u7 K% C5 O' e下面是结合亲和力比较强的一些药物：

3 d7 [) _" p6 [) S$ {$ H


+ O, m9 ?0 N8 X% X/ ^/ b! M其他一些研究的结论与这篇论文的结论是相印证的，试举几例如下：
, b6 \1 O, V& R" B3 S

3 a8 ]% F$ x7 D1 S$ {& R3 u1、《Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors》
; O4 s; ~4 v6 n' O
“MYC was identified as the most statistically repressed gene by DHE”



5 t. N) i5 O9 p2、《Drug repurposing and prediction of multiple interaction types via graph embedding》

“Two FDA approved drugs, Dihydroergotamine (CHEMBL1732) and Indinavir Sulfate (CHEMBL1735), which are predicted by the DT2Vec+, might be able to target MYC and decrease its expression. ”

& E; m1 I% _0 n2 |4 z# U

3、《Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells》
. ]/ x1 y: m* r! R
/ x. f8 w; ]; I. P6 i“PNT induced apoptosis (increased sub G1 cells, and cleaved caspase3 and PARP), and suppressed protein expression of MCL1, cyclin D2 and c-myc, which were reversed by a proteasome inhibitor, MG132, suggesting enhanced proteasomal degradation by PNT. ”

8 s7 t9 v0 W6 g" y
4、《 Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer》
/ j, E7 ]2 ~7 y7 \
4 i( H  _" T# k9 C+ x% w Additionally, treatment with eribulin resulted in a decrease in c-myc expression and a trend
toward an increase in cdki p15。
% H% x+ s) K: l6 q8 Y# l

9 [# g2 k# L0 ~5、《Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/β-catenin signaling》
" e; a, o, ?; i
3 c) Y( H& D* I% d* F9 Q“We also observed a decrease in c-Myc expression in the tumors of atovaquone-treated mice”